Compare Enveric Biosciences Inc (ENVB) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Kinder Morgan Inc — how do they compare? Enveric Biosciences Inc trades at $1.44 (market cap $6.80M), while Kinder Morgan Inc trades at $32.4 (market cap $71.81B). The key difference: Kinder Morgan Inc is far larger — about 10560.3× Enveric Biosciences Inc's market cap, and Kinder Morgan Inc pays a 3.66% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Kinder Morgan Inc for 150 Days on average.
| ENVB | KMI | |
|---|---|---|
Market Cap | $6.80M | $71.81B |
Volume | 64,867 | 16,921,908 |
Sector | Health | Energy |
52-Week High | $10.80 | $34.31 |
52-Week Low | $1.27 | $25.84 |
Typical Hold Time | 14 Days | 150 Days |
Enterprise Value | -$1.49M | $103.86B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Kinder Morgan (KMI) trades at $31.82, down 1.06% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $15.1B in 2024 to $16.9B in 2025 and net income margins expanding to 19.31%. Recent earnings beats in Q4 2025 through Q2 2026 highlight operational strength, while a $6B-$7B growth pipeline supports future expansion in natural gas infrastructure.
KMI presents a compelling investment case with analyst consensus target of $37.20 offering 17% upside potential. The stock's 4% dividend yield and consistent cash flow generation provide income stability, though exposure to energy market volatility and high debt levels ($29.66B long-term debt) remain key risks. Wall Street sentiment is balanced with 47% buy ratings versus 50% hold recommendations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
